Infliximab biosimilar Flixabi approved in the EU
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
List view / Grid view
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
18 January 2016 | By Victoria White
Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available there...
20 November 2015 | By Victoria White
Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel...
23 April 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...
29 July 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement...
27 February 2012 | By Biogen Idec
Samsung Biologics & Biogen Idec have established their joint venture...